Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial

INTRODUCTION: Growing evidence recommends antifibrinolytic agent tranexamic acid (TXA) to reduce blood loss and transfusions rate in various surgical settings. However, postoperative seizure, as one of the major adverse effects of TXA infusion, has been a concern that restricts its utility in neuros...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shu, Yan, Xiang, Li, Ruowen, Zhang, Xingyue, Ma, Tingting, Zeng, Min, Dong, Jia, Wang, Juan, Liu, Xiaoyuan, Peng, Yuming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Anaesthesia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811564/
https://www.ncbi.nlm.nih.gov/pubmed/35110315
http://dx.doi.org/10.1136/bmjopen-2021-052095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811564/
https://www.ncbi.nlm.nih.gov/pubmed/35110315
http://dx.doi.org/10.1136/bmjopen-2021-052095

Ejemplares similares